Stryker (SYK)
(Delayed Data from NYSE)
$369.56 USD
+9.83 (2.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $369.45 -0.11 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$369.56 USD
+9.83 (2.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $369.45 -0.11 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Zacks News
Stryker (SYK) to Gain From Solid Portfolio and Acquisitions
by Zacks Equity Research
Stryker's (SYK) diverse product portfolio alongside acquisition-driven strategy would continue to boost growth prospects. However, competition in the Chinese market raise concern.
Accuray's Radixact Now Used by Boise Summit Cancer Center
by Zacks Equity Research
Accuray's (ARAY) Radixact system leverages on its flagship TomoTherapy platform. The company's top-line growth is dependent on TomoTherapy system sales.
Globus Medical's Robotic Guidance System Gets FDA Approval
by Zacks Equity Research
Positive tidings on the regulatory front have favored Globus Medical (GMED) of late. The company's latest regulatory progress would lend it a competitive edge in the global niche space.
Cardiovascular Systems Unveils Favorable LIBERTY 360 Data
by Zacks Equity Research
LIBERTY 360 Study shows the importance of endovascular intervention in patients with Critical Limb Ischemia (CLI) to prevent amputation.
Anika (ANIK) Grows in Orthopedic Medicines on Positive Data
by Zacks Equity Research
Anika Therapeutics' (ANIK) data shows HYALOFAST as an effective treatment option for cartilage lesions, suitable to all age groups.
STERIS (STE) Banks on Organic Growth, Competition Intense
by Zacks Equity Research
STERIS' (STE) cost structure is likely to be enhanced through recent organizational changes.
Model N (MODN) Q3 Loss Narrower than Expected, Revenues Miss
by Zacks Equity Research
Model N (MODN) reported narrower-than-expected loss in the third quarter driven by better customer acquisition.
Is a Surprise in Store for Penumbra (PEN) in Q2 Earnings?
by Zacks Equity Research
Penumbra's (PEN) escalating costs and expenses may keep margins under pressure in the yet-to-be-reported second quarter.
Top Stock Reports for Procter & Gamble, Altria & Bristol-Myers
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Altria (MO) and Bristol-Myers (BMY).
The Zacks Analyst Blog Highlights: McDonald's, 3M, Stryker, Goldman Sachs and Kinder Morgan
by Zacks Equity Research
The Zacks Analyst Blog Highlights: McDonald???s, 3M, Stryker, Goldman Sachs and Kinder Morgan
Med-Products' Q2 Earnings Roster for Jul 27: ALGN, BSX & More
by Zacks Equity Research
The ongoing conflict related to healthcare policy implementation in the U.S. might get reflected in the Q2 results of these companies.
Why Earnings Season Could Be Great for Stryker Corporation (SYK)
by Zacks Equity Research
Stryker Corporation (SYK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.
Top Stock Reports for McDonald's, 3M & Stryker
by Zacks Equity Research
Today's Research Daily features new research reports on 16 major stocks, including McDonald's (MCD), 3M (MMM), and Stryker (SYK).
Ecolab (ECL) to Report Q2 Earnings: Will It Pull a Surprise?
by Zacks Equity Research
Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Ecolab's (ECL) growth in the second quarter.
Can Cerner (CERN) Deliver a Beat this Earnings Season?
by Zacks Equity Research
We believe Cerner's (CERN) strong sales performance, solid portfolio and strategic initiatives have positioned it for stellar growth.
Can Henry Schein (HSIC) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
The timing of Good Friday is likely to dampen sales at Henry Schein (HSIC) in second-quarter 2017. Meanwhile, geographic expansion should continue.
Can Illumina (ILMN) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Illumina (ILMN) is well poised to witness steady top-line growth in Q2. Yet, the bottom line may remain stressed.
Will Stryker (SYK) Deliver a Beat this Earnings Season?
by Zacks Equity Research
The growing adoption of Stryker's (SYK) MAKO robots is expected to drive second-quarter 2017 sales in the orthopedic and reconstructive surgery market.
Is a Surprise in Store for ResMed (RMD) in Q4 Earnings?
by Zacks Equity Research
Currency headwind is likely to dampen ResMed's (RMD) gains in the COPD and sleep apnea market.
McKesson (MCK) Q1 Earnings: Stock Likely to Beat Estimates?
by Zacks Equity Research
McKesson's (MCK) strategic acquisitions and promising guidance raise optimism for the first quarter of fiscal 2018.
IDEXX Laboratories (IDXX) Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) Companion Animal Group business might drive its performance in Q2.
What's in Store for Express Scripts (ESRX) in Q2 Earnings?
by Zacks Equity Research
Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Express Scripts' (ESRX) growth in the second quarter.
Baxter International (BAX) Q2 Earnings: What's in Store?
by Zacks Equity Research
Despite an upbeat guidance, lower cyclophosphamide sales are likely to mar Baxter International (BAX) performance in the second quarter 2017.
Varian Medical (VAR) Q3 Earnings: Is a Surprise in Store?
by Zacks Equity Research
Varian Medical Systems' (VAR) oncology business strength might drive its performance in Q3.
Align Technology (ALGN) Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
Align Technology (ALGN) might ride high in Q2 banking on growth in the Invisalign space.